Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp201 | Cell biology: osteoblasts and bone formation | ECTS2013

Primary Human Bone Cells treated with Parathyroid Hormone or Dexamethasone show Effects on micro-RNA Expression Patterns Assessed by Second Generation Sequencing

Laxman Navya , Rubin Carl-Johan , Mallmin Hans , Nilsson Olle , Tellgren-Roth Christian , Kindmark Andreas

Introduction: Micro-RNAs (miRNAs) are important post-transcriptional regulators. By binding to complementary RNA strands, they affect mRNA levels and/or mRNA translation. We have previously identified ~90 miRNAs with significant expression levels, with a subset of miRNAs exhibiting interindividual and/or gender differences in expression. In the present project, we have investigated the impact of treatment of parathyroid hormone (PTH) and dexamethasone (DEXA) on global miRNA ex...

ba0005oc3.5 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Low serum iron is associated with high serum FGF23 in elderly men: the Swedish MrOS study

Lewerin Catharina , Ljunggren Osten , Nilsson-Ehle Herman , Karlsson Magnus K , Herlitz Hans , Lorentzon Mattias , Ohlsson Claes , Mellstrom Dan

Introduction: Fibroblast growth factor (FGF23) is a hormone derived from osteoblasts and osteocytes being involved in calcium and phosphate homeostasis, where serum iron (S-Fe) has been suggested as a potential mediator of FGF23 regulation. The aim was to determine whether iron status is a determinant of FGF23 in elderly men.Methods: The MrOS (osteoporotic fractures in men is a population based study of elderly men, in the Gothenburg part, (median age of...

ba0007oc14 | (1) | ICCBH2019

Burosumab resulted in greater improvement in clinical outcomes than continuation with conventional therapy in younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia

Ward Leanne , Imel Erik , Whyte Michael , Munns Craig , Portale Anthony , Hogler Wolfgang , Simmons Jill , Padidela Raja , Namba Noriyuki , Cheong Hae , Nilsson Ola , Mao Meng , Skrinar Alison , Chen Chao-Yin , Martin Javier San , Glorieux Francis

Objective: We compared the efficacy and safety of burosumab, a monoclonal antibody against FGF23, to conventional therapy [oral phosphate and active vitamin D (Pi/D)] in children with X-linked hypophosphatemia (XLH).Methods: In this Phase 3 trial (NCT02915705), 61 children with XLH (1-12 years-old) were randomized 1:1 after a 7-day Pi/D washout to receive burosumab starting at 0.8 mg/kg SC Q2W or reinitiate Pi/D optimally titrated by investigators. Eligi...